Jury Rejects Feds’ Claims Gilead Infringed HIV Drug Patents

May 9, 2023

WILMINGTON, DE – On Tuesday, a six-person federal jury in Delaware rejected a potential $1 billion government claim that Gilead Sciences Inc. violated government-owned patents when it released its Truvada and Descovy medications to treat or lower the risk of HIV infections.

Impact Trial worked with a team of lawyers from Wilmer Cutler Pickering Hale and Dorr LLP, on behalf of their client Gilead Sciences Inc.

Congratulations to our Impact team members Thomas S.Y. Lee, Jennifer Gustavson, Jenny Phillips, Michael Kang, Stu Lucero, Clinton Lam, Brian Lee, and Paul Matsinger and the WilmerHale team on this win!

The suit is U.S. v. Gilead Sciences Inc. et al., case number 1:19-cv-02103, in the U.S. District Court for the District of Delaware.